Eponyms in Oncology: Lynch Syndrome
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of Lynch syndrome.
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of Lynch syndrome.
Fuzuloparib maintenance significantly delayed the time to disease progression and time to subsequent chemotherapy.
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of HeLa cells.
The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.
The risk of breakthrough SARS-CoV-2 infections was highest for liver cancer and lowest for thyroid cancer.
The median duration of response was significantly longer with rucaparib than with standard chemotherapy.
Patients who have mismatch repair proficiency in the primary setting may have mismatch repair deficiency at recurrence.
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of Virchow’s node.
Despite the lack of improvement in the overall cohort, olaparib monotherapy and olaparib-cediranib did exhibit activity in a subset of patients with a germline BRCA mutation.
The risk for kidney failure requiring renal replacement therapy varies by cancer type, with multiple myeloma associated with the highest risk.